ClinicalTrials HQ

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Active, not recruiting · NCT06788938 · Registry updated 2026-09-01
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine NeoplasmsneoplasmActive, not recruitingPhase 22026-09-01NCT06788938

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Amgen180
Jonsson Comprehensive Cancer Center115

5 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
UC Davis Comprehensive Cancer CenterDavisUnited States1
UC San Diego Moores Cancer CenterSan DiegoUnited States3
UCI Health Chao Family Comprehensive Cancer CenterIrvineUnited States1
University of California at Los AngelesLos AngelesUnited States14
University of California at San FranciscoSan FranciscoUnited States12